Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Abd El Atti, Rasha M ^a   Abou Gabal, Hoda H ^a   Osman, Wesam M ^a   Saad, Amr S ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Astrocytoma; DJ 1; Immunohistochemistry; MIB 1; Prognosis

Indexed keywords

ANTINUCLEAR ANTIBODY; DIAGNOSTIC AGENT; KI 67 ANTIGEN; MIB 1 ANTIBODY; MIB-1 ANTIBODY; MONOCLONAL ANTIBODY; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; CANCER GRADING; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883627470     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-126     Document Type: Article

References (41)

1. Ambroise MM, Khosla C, Ghosh M, Mallikarjuna VS, Annapurneswari S. Practical value of MIB-1 index in predicting behavior of astrocytomas. Indian J Pathol Microbiol 2011, 54:520-525.
2. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006, 12(3):143-147. 10.1007/BF02893360, 16998593.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization classification of tumors of the central nervous system 2007, Lyon, France: International Agency for Research Press.
4. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997, 56:798-805.
5. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999, 58:46-53. 10.1097/00005072-199901000-00006, 10068313.
6. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006, 103:15091-15096. 10.1073/pnas.0607260103, 1586179, 17015834.
7. Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem 2008, 105:2435-2453. 10.1111/j.1471-4159.2008.05333.x, 18331584.
8. Junn E, Taniguchi H, Jeong B, Zhao X, Ichijo H, Mouradian M. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci USA 2005, 102:9691-9696. 10.1073/pnas.0409635102, 1172235, 15983381.
9. Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P, Wu M, Wang G. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem 2008, 283:4022-4030.
10. Yuen HF, Chan YP, Law S, Srivastava G, El-tanani M, Mak TW, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:3593-3602. 10.1158/1055-9965.EPI-08-0214, 19064576.
11. Le-Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7:3328-3335.
12. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as over expressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241. 10.1186/1471-2407-8-241, 2528014, 18706098.
13. Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004, 127:420-430. 10.1093/brain/awh054, 14662519.
14. Mullett SJ, Hamilton RL, Hinkle DA. DJ-1 immunoreactivity in human brain astrocytes is dependent on infarct presence and infarct age. Neuropathology 2009, 29:125-131. 10.1111/j.1440-1789.2008.00955.x, 18647263.
15. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J. Neuro-Oncol 1996, 27:65-73.
16. Burger PC, Nelson JS, Boyko OB. Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. Arch Pathol Lab Med 1998, 122:609-619.
17. Kleinhues P, Cavence WK. World health organization classification of tumors. Pathology & genetics. Tumors of the nervous system 2000, Lyon: IARC Press.
18. Brat DJ, Parisi JE, Kleinschmidt BK, Yachnis AT, Montine TJ, Boyer PJ, et al. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumors of the central nervous system, 4th edition. Arch Pathol 2008, 132:993-1007.
19. Gomori E, Pal J, Kovacs B, Doczi T. Concurrent hyprmethylation of DNMT1. MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012, 7:8. 10.1186/1746-1596-7-8, 3292961, 22264301.
20. Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH. Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol 2010, 5:18. 10.1186/1746-1596-5-18, 2859381, 20331873.
21. Lind-Landstrom T, Varughese RK, Sundstrom S, Torp SH. Expression and clinical significance of the proliferation marker minichromosome maintenance protein2 (Mcm2) in diffuse astrocytomas WHO grade II. Diagn Pathol 2013, 8:67. 10.1186/1746-1596-8-67, 3648352, 23618321.
22. Habberstad AH, Gulati S, Torp SH. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3 and DNA topoisomerase ll alpha in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol 2011, 6:43. 10.1186/1746-1596-6-43, 3127815, 21609421.
23. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns BJ, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 1994, 34:674-678. 10.1227/00006123-199404000-00016, 8008166.
24. Lindboe CF, Torp SH. Comparison of Ki-67 equivalent antibodies. J Clin Pathol 2002, 55:467-471. 10.1136/jcp.55.6.467, 1769671, 12037032.
25. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1(Ki-67) immunoreactivity in differentiating grade II and grade III Gliomas. J Neuropathol Exp Neurol 1997, 56:857-865. 10.1097/00005072-199708000-00003, 9258255.
26. Rathi KR, Radotra BD, Khosla VK. Proliferative index in astrocytic tumours. Indian J Pathol Microbiol 2007, 50:754-758.
27. Rodriguez-Pereira C, Suárez-Penaranda JM, Vázquez-Salvado M, Sobrido MJ, Abraldes M, Barros F, et al. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. J Neurosurg Sci 2000, 44:203-210.
28. Ho DM, Wong TT, Hsu CY, Ting LT, Chiang H. MIB-1 labeling index in non pilocytic astrocytoma of childhood: a study of 101 cases. Cancer 1998, 82:2459-2466. 10.1002/(SICI)1097-0142(19980615)82:12<2459::AID-CNCR21>3.0.CO;2-N, 9635540.
29. Tihan T, Davis R, Elowitz E, DiCostanzo D, Moll U. Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med 2000, 124:108-113.
30. Enestrom S, Vavruch L, Franlund B, Nordenskjold B. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie 1998, 44:25-30.
31. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 1992, 66:373-385. 10.1038/bjc.1992.273, 1977794, 1503912.
32. Neder L, Colli BO, Machado HR, Carlotti CG, Santos AC, Chimelli L. MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol 2004, 23:262-270.
33. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996, 77:373-380. 10.1002/(SICI)1097-0142(19960115)77:2<373::AID-CNCR21>3.0.CO;2-Y, 8625247.
34. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: An immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatr 1995, 59:413-419. 10.1136/jnnp.59.4.413, 486079, 7561922.
35. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 1998, 57:931-936. 10.1097/00005072-199810000-00005, 9786243.
36. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 2002, 58:203-215. 10.1023/A:1016261900413, 12187956.
37. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 2006, 76:193-200. 10.1007/s11060-005-5262-1, 16234986.
38. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res 2009, 87:123-129. 10.1002/jnr.21831, 2752655, 18711745.
39. Hinkle DA, Mullett SJ, Gabris BE, Hamilton RL. DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification. Neuropathology 2011, 31:29-37. 10.1111/j.1440-1789.2010.01124.x, 20497343.
40. Miyajima Y, Sato Y, Okai H, Utsuki S, Kondo K, Tanizaki Y, et al. Prognostic Significance of Nuclear DJ-1 Expression in Astrocytoma. Anticancer Res 2010, 30:265-270.
41. Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2008, 39:87-95. 10.1016/j.humpath.2007.05.014, 17949781.